Pegylated Liposomal Doxorubicin

Cytostatic · Cytotoxic antibiotic

Indications

Treatment of patients with Ovarian cancer whose disease has progressed or recurred after failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy. In combination with bortezomib for the treatment of patients with Multiple myeloma (who have not previously received bortezomib and have received at least one prior therapy).

Dosage

Adults: Ovarian cancer: 50 mg/m2 intravenously over 60 mins every 4 wks. AIDS-related Kaposi’s Sarcoma: 20 mg/m2 intravenously over 60 mins every 3 wks. Multiple Myeloma: 30 mg/m2 intravenously over 60 mins on day 4 (after bortezomib) of each 21-day cycle for 8 cycles or until disease progression or unacceptable toxicity. Children: Not recommended.

Administration

Administer intravenously at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related reactions occur, increase rate of infusion to complete administration over 1 hr. Do not administer as bolus injection or undiluted solution. Inspect parenteral drug products visually for particulate matter and discolouration prior to adm, whenever solution and container permit. Do not use if a precipitate or foreign matter is present. Do not use with in-line filters. Reconstitution: Dilute doxorubicin HCl liposome inj doses up to 90 mg in 250 mL of 5% Dextrose Inj prior to administration. Dilute doses exceeding 90 mg in 500 mL of 5% Dextrose Inj, prior to administration. Refrigerate diluted doxorubicin HCl liposome inj at 2-8°C and administer within 24 hrs. Compatibility: D5W. Stability: Store diluted soln at 2-8°C.

Adverse Effects

Fatigue, nausea, vomiting, diarrhoea, fever, asthenia, anorexia, stomatitis, constipation, hand-foot syndrome, rash, neutropaenia, thrombocytopaenia, and anaemia.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Assess left ventricular cardiac function prior to initiation of medication and during and after treatment. Withhold treatment for infusion-related reactions and resume at a reduced rate. Discontinue for serious or life-threatening infusion-related reactions. Reduce dose for serum bilirubin of 1.2 mg/dL or higher.

Advice to Patient

Report new onset fever or symptoms of infection. Report tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of hands or soles of feet (symptoms of Hand-Foot syndrome). Report if you develop painful redness, swelling or sores in the mouth (stomatitis). Females and males of reproductive potential should use effective contraception during and for 6 months after treatment. Lactating females must avoid nursing their babies during treatment.

Pharmacokinetics

Metabolism: Hepatic.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.